Target intelligence / Profile preview

Lipid IIIWTA pyrophosphate moiety (Lipid IIIWTA)

Target
Lipid IIIWTA
Molecular classification
Bacterial cell wall precursor, Glycolipid, Lipid-linked intermediate
01

Overview

Lipid IIIWTA is a critical lipid-linked intermediate in the biosynthesis of wall teichoic acids (WTA) in Gram-positive bacteria. It consists of an undecaprenyl carrier linked via a pyrophosphate (diphosphate) group to a sugar-polyol chain, typically comprising N-acetylglucosamine, N-acetylmannosamine, and glycerol-phosphate or ribitol-phosphate units (Pereira et al., 2008; Brown et al., 2013). The pyrophosphate moiety of Lipid IIIWTA serves as a highly conserved and essential target for a new class of antibiotics, including teixobactin and clovibactin (Ling et al., 2015; Shukla et al., 2023). These drugs bind tightly to the pyrophosphate group, effectively sequestering the precursor and halting the assembly of the bacterial cell wall (Weingarth et al., 2023). Because the pyrophosphate moiety is a fundamental structural component that does not vary between bacterial strains, drugs targeting this site are less prone to the development of resistance. Inhibition of Lipid IIIWTA synthesis leads to a deficiency in WTAs, which are vital for maintaining cell wall integrity, regulating autolytic enzymes, and facilitating host-pathogen interactions (Homma et al., 2016).

Other names
Lipid III (WTA)Wall teichoic acid precursor Lipid IIIUndecaprenyl-pyrophosphate-GlcNAc-ManNAc-GroPUndecaprenyl-diphospho-N-acetylglucosaminyl-N-acetylmannosaminyl-glycerolphosphate
02

Mechanism of action

Binding to the conserved pyrophosphate moiety of lipid-linked cell wall precursors, leading to inhibition of wall teichoic acid and peptidoglycan synthesis, and subsequent cell lysis.

03

Biological functions

Wall teichoic acid biosynthesisCell wall assemblyRegulation of autolysinsBacterial cell envelope maintenance
04

Disease associations

Bacterial infectionMethicillin-resistant Staphylococcus aureus (MRSA) infectionVancomycin-resistant Enterococci (VRE) infection
05

Safety considerations

Potential for off-target effects on other lipid-linked processes (though minimal in humans)Poor solubility of some targeting drugs (e.g., Teixobactin)Delivery to the site of infection
06

Interacting drugs

Teixobactin

1 more in the full profile.

07

Biomarkers

UDP-N-acetylmuramic acid pentapeptide accumulationWall teichoic acid levelsBacterial cell lysis markers

Beyond the preview

Go deeper on Lipid IIIWTA pyrophosphate moiety (Lipid IIIWTA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipid IIIWTA pyrophosphate moiety (Lipid IIIWTA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call